Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivan King

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapyIvan King, Martina Itterson, David Bermudes
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 24, 2015
Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male ratsAla F Nassar, Adam Wisnewski, Ivan King
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 22, 2016
Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patientsAla F Nassar, Adam V Wisnewski, Ivan King
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 10, 2016
Biotransformation and Rearrangement of LaromustineAlaa-Eldin F Nassar, Adam V Wisnewski, Ivan King
Cancer Chemotherapy and Pharmacology|January 27, 2007
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor modelsLi-mou Zheng, Zujin Li, Lanzhen Liu, et al.
Journal of Chromatographic Science|November 6, 2018
Development and Validation of LC-MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human PlasmaAla F Nassar, Adam V Wisnewski, Terence Wu, et al.
Methods in Molecular Medicine|December 6, 2003
Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humansKenneth Brooks Low, Martina Ittensohn, Xiang Luo, et al.
Investigational New Drugs|April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activityArun A Azad, Howard Gurney, Craig Underhill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapyFrank Friedlos, Panos Lehouritis, Lesley Ogilvie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Methods in Molecular Biology (Clifton, N.J.)|July 2, 2009
Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapyIvan King, Martina Itterson, David Bermudes
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|March 24, 2015
Metabolic disposition of the anti-cancer agent [(14)C]laromustine in male ratsAla F Nassar, Adam Wisnewski, Ivan King
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|July 22, 2016
Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patientsAla F Nassar, Adam V Wisnewski, Ivan King
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 10, 2016
Biotransformation and Rearrangement of LaromustineAlaa-Eldin F Nassar, Adam V Wisnewski, Ivan King
Cancer Chemotherapy and Pharmacology|January 27, 2007
Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor modelsLi-mou Zheng, Zujin Li, Lanzhen Liu, et al.
Journal of Chromatographic Science|November 6, 2018
Development and Validation of LC-MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human PlasmaAla F Nassar, Adam V Wisnewski, Terence Wu, et al.
Methods in Molecular Medicine|December 6, 2003
Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humansKenneth Brooks Low, Martina Ittensohn, Xiang Luo, et al.
Investigational New Drugs|April 27, 2025
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activityArun A Azad, Howard Gurney, Craig Underhill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapyFrank Friedlos, Panos Lehouritis, Lesley Ogilvie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluationDouglas H Thamm, Ilene D Kurzman, Ivan King, et al.
Pageof 2